A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP

Summary

A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks including a washout period.

Timeline

Start

2020-06-22

Primary completion

2022-07-18

Completion

2024-09-30

Outcome

Met primary endpoint

release “The primary objectives of the study were met, namely the investigational product good safety and tolerability in PSP patients.” alzprotect.com ↗

Drugs

Indications